Papers
1
Total Citations
13
H-Index
1
About
Gang Zhao is an oncology researcher whose work centers on esophageal cancer treatment, with a particular focus on advancing neoadjuvant therapeutic strategies for locally advanced disease. His most notable contribution is the Keystone-001 trial, a prospective phase II study investigating the combination of pembrolizumab — a prominent immune checkpoint inhibitor — with paclitaxel and cisplatin as a neoadjuvant regimen for patients with stage III esophageal squamous cell carcinoma. This work represents a meaningful step forward in the multimodal management of a cancer type that carries a notoriously poor prognosis, exploring how immunotherapy can be integrated with conventional chemotherapy prior to surgical resection to improve outcomes in resectable cases. Published in 2021, the interim analysis of this single-center trial has already garnered 13 citations, reflecting early interest from the oncology community in its findings. Zhao's research speaks to a broader effort to refine treatment sequencing and expand the role of immunotherapy in gastrointestinal cancers, offering potential pathways toward improved survival and resectability for patients with this challenging diagnosis.
Research Focus
Key Achievements
Top Papers
- 1